Table 3. Univariate and multivariate analysis of factors related to SVR24.
Covariates with a p-value<0.2 under univariate analysis were included in the multivariate model.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| %SVR24 | P | P | Odds ratio | 95% CI | ||
| Before treatment | ||||||
| Recipient IL28B status (CC/CT/TT) | 86/57/38 | 0.098 | ||||
| BMI (Kg/m2) >25 | 50 | 0.099 | ||||
| Fibrosis stage ≤F2 vs >F2 | 53 vs 30 | 0.060 | ||||
| Null response post-LT | 47 | 0.190 | ||||
| Bilirubin level <17μmol/L | 28 | 0.013 | 0.015 | 5.484 | 1.402 | 21.453 |
| Albumin level >35g/L | 54 | 0.026 | 0.037 | 4.604 | 1.094 | 19.366 |
| MELD score ≤10 | 54 | 0.024 | ||||
| Cyclosporine use | 50 | 0.014 | ||||
| No steroid use | 47 | 0.040 | ||||
| Boceprevir use | 52 | 0.087 | ||||
| Baseline RBV dose ≥800mg/day | 58 | 0.004 | 0.003 | 9.775 | 2.139 | 44.673 |
| During treatment | ||||||
| EVR | 70 | <0.00001 | 0.001 | 49.394 | 5.791 | 421.277 |
| No premature discontinuation for SAE | 66 | 0.04 | 0.022 | 6.360 | 1.300 | 31.115 |
| Treatment duration | 73 | 0.08 | ||||
Abbreviations: BMI: body mass index; EVR: early virological response; RBV: ribavirin; SAE: serious adverse event; SVR24: sustained virological response 24 weeks after treatment discontinuation; vs: versus.